Shilpa Medicare Ltd (SHILPAMED)
₹606.20
Mkt cap
₹11,856 Cr
P/E ratio
50.80
P/B
4.59
Div yield
0.08%
ROE
9.40%
ROCE
11.00%
EPS (TTM)
₹11.93
Book value
₹132
52W range
267–646
Sector
Healthcare
Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics. [1]
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−6.12% from high₹606
₹267+127.04% from low₹646
Current
₹606.20
Prev close
₹605.00
Day
+0.20%
Price performance
1D
+0.20%
1W
−3.08%
1M
+6.05%
3M
+46.46%
6M
+117.12%
1Y
+31.42%
YTD
+89.56%
Financials
FRevenue, profit & margin
P/E ratio
50.8×
SHILPAMED is 49% above the sector median of 34.0×
SHILPAMED50.8×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 264 | 260 | 313 | 287 | 292 | 293 | 344 | 319 | 331 | 321 | 370 | 410 | 437 | |
| Expenses | 227 | 214 | 255 | 222 | 222 | 222 | 258 | 239 | 252 | 231 | 262 | 296 | 317 | |
| Operating Profit | 37 | 46 | 58 | 65 | 70 | 70 | 86 | 81 | 79 | 91 | 108 | 114 | 120 | |
| OPM % | 14% | 18% | 19% | 23% | 24% | 24% | 25% | 25% | 24% | 28% | 29% | 28% | 27% | |
| Other Income | 2 | 2 | 2 | 2 | 9 | 10 | 5 | 2 | -21 | 6 | 2 | -13 | 45 | |
| Interest | 18 | 18 | 23 | 26 | 24 | 24 | 26 | 12 | 14 | 19 | 16 | 11 | 14 | |
| Depreciation | 26 | 27 | 28 | 27 | 27 | 27 | 28 | 29 | 29 | 29 | 30 | 30 | 31 | |
| Profit before tax | -4 | 3 | 9 | 14 | 28 | 29 | 37 | 42 | 15 | 50 | 64 | 61 | 120 | |
| Tax % | 90% | 64% | 83% | 67% | 12% | 51% | 51% | 24% | 5% | 5% | 32% | 27% | 10% | |
| Net Profit | -8 | 1 | 2 | 5 | 24 | 14 | 18 | 32 | 15 | 47 | 44 | 45 | 108 | |
| EPS in Rs | -0.46 | 0.07 | 0.09 | 0.26 | 1.41 | 0.72 | 0.92 | 1.62 | 0.74 | 2.40 | 2.25 | 2.28 | 5.51 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202640.13%Promoter
Promoters40.13%
FIIs11.39%0.32
DIIs8.05%0.53
Public40.42%0.21
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Shilpa Medicare | ₹606.20 | 50.82 | 11,856 | 0.08% | 108 | +147.82% | 437 | +32.09% | 11.03% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013nseFinancial Year 2013bseFinancial Year 2012bse
Concall transcripts54
TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptJul 2024TranscriptMay 2024PPTMay 2024PPTMay 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Credit Rating 16 Jul - India Ratings assigned IND A+/Stable and IND A1+ to Shilpa Biologicals’ INR1,250 million bank facilities.Announcement under Regulation 30 (LODR)-Change in Management 15 Jul - Dr. Sridevi Khambhampaty resigned as CEO of Shilpa Biologicals, effective closing hours 15 July 2026.Announcement under Regulation 30 (LODR)-Credit Rating 7 Jul - India Ratings upgraded Shilpa Medicare and subsidiary bank facilities to IND AA-/Stable on 7 July 2026.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Jul - Regulation 74(5) compliance certificate filed for quarter ended 30 June 2026.Announcement under Regulation 30 (LODR)-Press Release / Media Release 30 Jun - Shilpa Biologicals signs co-development and supply deal with Orion for nivolumab biosimilar in Europe.